Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01632306 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01632306 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 13 participants.
The verdict
NCT01632306, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG FOLFOX
- DRUG LY2090314
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01632306
The ClinicalTrials.gov registry entry for NCT01632306 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Gemcitabine is the first listed.
NCT01632306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01632306 about?
NCT01632306 is a clinical study titled "A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer". Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.
What is the current status of trial NCT01632306?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2013-03. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01632306?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), FOLFOX (DRUG), LY2090314 (DRUG).
Who is sponsoring clinical trial NCT01632306?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.